Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SOD1 | P00441 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 10/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | PNLIP | P16233 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18290303 | 0.87 | SOD1 (0.38) | CYP3A4TP53SOD1 | |
| SCHEMBL16499400 | 0.63 | ALOX15 (0.34) | ALOX15 | |
| SCHEMBL12821787 | 0.63 | ALOX15 (0.34) | ALOX15 | |
| Ugandensolide SCHEMBL21025899 | 0.63 | MAPK1 (0.31) | CYP3A4CYP19A1KMT2A | |
| SCHEMBL12194936 | 0.62 | KARS1 (0.52) | CYP3A4TP53FDPSGGPS1ALDH1A1 | |
| SCHEMBL18290200 | 0.61 | SOD1 (0.76) | CYP3A4TP53SOD1FDPSGGPS1 | |
| SCHEMBL18290240 | 0.60 | FDPS (0.48) | CYP3A4TP53FDPSGGPS1ALDH1A1 | |
| SCHEMBL18290302 | 0.59 | SOD1 (0.47) | SOD1FDPSCYP19A1PTGESPNLIP | |
| SCHEMBL3462790 | 0.58 | CYP3A4 (1.00) | CYP3A4TP53MAPTALOX15CYP19A1 | |
| SCHEMBL5527006 | 0.58 | CYP3A4 (1.00) | CYP3A4TP53MAPTALOX15CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296683-A1 | ORAL DELIVERY SYSTEM | UNIVERSITY COLLEGE DUBLIN (IE) | 2022-09-22 | — | — | US | disclosed |
| EP-4021408-A1 | ORAL DELIVERY SYSTEM | University College Dublin (IE) | 2022-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296683-A1 | ORAL DELIVERY SYSTEM | GLP1R, GIPR, IAPP | CYP3A4 3459/4885TP53 2750/4885SOD1 1661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.